Heart Failure
RSSArticles
-
Is It Better to Up-Titrate Medications Faster in Acute Heart Failure Patients?
Early intensive up-titration of guideline-recommended therapy in patients admitted for heart failure reduced 180-day readmission and all-cause mortality at the cost of more adverse events (but not serious or fatal ones).
-
Importance of Medication Adherence in Ischemic Heart Disease
The results of a subanalysis of the ISCHEMIA trial indicated about one-quarter of patients in both conservative and invasive strategy groups were nonadherent to recommended medical therapy at baseline. Nonadherence was associated with worse health status in both groups at baseline and after one year.
-
Top Heart Medication Could Help Alcohol Use Disorder Patients
Spironolactone is known to block mineralocorticoid receptors, an action believed to reduce alcohol cravings.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin to placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin vs. placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Searching for the Best Echo Parameter to Predict Aortic Stenosis Outcomes
In a study of two large echocardiographic databases, the authors observed maximum aortic velocity exhibits a strong linear relationship, with the risk of mortality starting at velocities of 100 cm/s, whereas calculated aortic valve area was not related to mortality until the valve area was <1.5 cm2.